Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Mutations in hmg1, Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus.

Rybak JM, Ge W, Wiederhold NP, Parker JE, Kelly SL, Rogers PD, Fortwendel JR.

MBio. 2019 Apr 2;10(2). pii: e00437-19. doi: 10.1128/mBio.00437-19.

2.

Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris.

Rybak JM, Doorley LA, Nishimoto AT, Barker KS, Palmer GE, Rogers PD.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e00057-19. doi: 10.1128/AAC.00057-19. Print 2019 Apr.

3.

Emerging threat of triazole-resistant Aspergillus fumigatus.

Rybak JM, Fortwendel JR, Rogers PD.

J Antimicrob Chemother. 2019 Apr 1;74(4):835-842. doi: 10.1093/jac/dky517.

PMID:
30561652
4.

Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Rybak JM, Dickens CM, Parker JE, Caudle KE, Manigaba K, Whaley SG, Nishimoto AT, Luna-Tapia A, Roy S, Zhang Q, Barker KS, Palmer GE, Sutter TR, Homayouni R, Wiederhold NP, Kelly SL, Rogers PD.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00651-17. doi: 10.1128/AAC.00651-17. Print 2017 Sep.

5.

An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis.

Peters BM, Luna-Tapia A, Tournu H, Rybak JM, Rogers PD, Palmer GE.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00084-17. doi: 10.1128/AAC.00084-17. Print 2017 Jun.

6.

Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.

Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD.

Front Microbiol. 2017 Jan 12;7:2173. doi: 10.3389/fmicb.2016.02173. eCollection 2016. Review.

7.

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.

Brade KD, Rybak JM, Rybak MJ.

Infect Dis Ther. 2016 Mar;5(1):1-15. doi: 10.1007/s40121-016-0103-4. Epub 2016 Feb 1. Review.

8.

Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.

Autry EB, Rybak JM, Leung NR, Gardner BM, Burgess DR, Anstead MI, Kuhn RJ.

Pharmacotherapy. 2016 Jan;36(1):13-8. doi: 10.1002/phar.1681. Epub 2016 Jan 9.

PMID:
26748559
9.

Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.

Rybak JM, Marx KR, Nishimoto AT, Rogers PD.

Pharmacotherapy. 2015 Nov;35(11):1037-51. doi: 10.1002/phar.1652. Epub 2015 Nov 2. Review.

PMID:
26598096
10.

The β-Lactams Strike Back: Ceftazidime-Avibactam.

Zasowski EJ, Rybak JM, Rybak MJ.

Pharmacotherapy. 2015 Aug;35(8):755-70. doi: 10.1002/phar.1622. Review.

11.

Tedizolid Phosphate: a Next-Generation Oxazolidinone.

Rybak JM, Roberts K.

Infect Dis Ther. 2015 Feb 24. [Epub ahead of print]

12.

Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy.

Tennant SJ, Burgess DR, Rybak JM, Martin CA, Burgess DS.

Antibiotics (Basel). 2015 Dec 11;4(4):643-52. doi: 10.3390/antibiotics4040643.

13.

Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.

Rybak JM, Marx K, Martin CA.

Pharmacotherapy. 2014 Nov;34(11):1198-208. doi: 10.1002/phar.1491. Epub 2014 Sep 30. Review.

PMID:
25266820
14.

Current and prospective treatments for multidrug-resistant gram-positive infections.

Rybak JM, Barber KE, Rybak MJ.

Expert Opin Pharmacother. 2013 Oct;14(14):1919-32. doi: 10.1517/14656566.2013.820276. Epub 2013 Jul 22. Review.

PMID:
23876168

Supplemental Content

Loading ...
Support Center